Neogen (NEOG) Q2 Earnings Miss Estimates
Neogen (NEOG) delivered earnings and revenue surprises of -41.18% and 1.10%, respectively, for the quarter ended November 2021. Do the numbers hold clues to what lies ahead for the stock?
Neogen (NEOG) came out with quarterly earnings of $0.10 per share, missing the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.15 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -41.18%. A quarter ago, it was expected that this maker of medical testing kits would post earnings of $0.15 per share when it actually produced earnings of $0.16, delivering a surprise of 6.67%.
Over the last four quarters, the company has surpassed consensus EPS estimates just once.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Neogen shares have added about 11.8% since the beginning of the year versus the S&P 500's gain of 21.6%.
What's Next for Neogen?
While Neogen has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Neogen: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.15 on $130 million in revenues for the coming quarter and $0.66 on $526.4 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 26% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the broader Zacks Medical sector, AngioDynamics (ANGO), is yet to report results for the quarter ended November 2021. The results are expected to be released on January 6.
This medical device maker is expected to post break-even quarterly earnings per share in its upcoming report, which represents a year-over-year change of -100%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
AngioDynamics' revenues are expected to be $77.97 million, up 7.2% from the year-ago quarter.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.See these 7 breakthrough stocks now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Neogen Corporation (NEOG): Free Stock Analysis Report
AngioDynamics, Inc. (ANGO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research